Progesterone Market

Global Progesterone Market Size (2023 to 2028)

The global progesterone market is forecasted to grow with a CAGR of 14.4% between 2023 to 2028. As a result, the market size is estimated to grow to USD 1795 million by 2028 from USD 916.1 million in 2023.

Progesterone is an endogenous steroid secreted throughout the second half of the menstrual cycle by the corpus luteum, a temporary endocrine gland that the female body releases after ovulation. This represents a group of hormones known as progestogens and is the body's primary progestogen. Progesterone generally involves pregnancy maintenance, menstrual cycle regulation, and embryogenesis. Low progesterone levels can prompt consistent breast tenderness, stomach agony, weariness, and even miscarriage or fetal death. At this point, to avoid the conditions described above, progesterone is given to the patient. There are many applications for progesterone. This steroid can treat the absence of menstrual periods or Amenorrhea. It is used in Hormone Replacement Therapy (HRT) with estrogen. It is also used to treat women with infertility. The vaginal application of progesterone decreases breast pain and tenderness in women. This eliminates the effects of menopause and reduces the risk of premature delivery and many other applications.

MARKET DRIVERS:

The growing prevalence of uterine bleeding and amenorrhea is one of the significant factors accelerating the global progesterone market growth. Incidences of diseases such as abnormal uterine bleeding and Amenorrhea are predicted to rise, as is the female population affected by these diseases. Most of the market is made up of postmenopausal women. As a result, the expanding number of menopausal windows and the growing female population in the 45–59-year age bracket are expected to boost the total market growth. Synthetic progesterone or progestins are also employed as a diagnostic tool to examine the effects of oestrogen due to technical developments in the medical industry. Progesterone is used in a variety of ways. In Hormone Replacement Therapy, it's used with estrogen. It's also utilized in the treatment of female infertility. Because of their improved treatment methods, the global progesterone market is projected to develop rapidly in the coming years. The worldwide progesterone market is being driven by an increase in the prevalence of Amenorrhea, which is the absence of monthly periods and a rise in infertility treatment in women, uterine death, breast cancer, and other factors.

An increase in the prevalence of breast cancer in women is expected to be a significant growth driver since breast cancer patients may have breast pain, for which the progesterone hormone is one of the therapeutic choices. As a result, progesterone usage is expected to rise. The availability of frequently monitored formulations, technical developments in drug delivery systems, and more patient awareness drive the demand for progesterone. The progesterone market is also expected to benefit from a wide range of pipeline medicines that are likely to be approved in clinical trials. During the forecast period, natural progesterone is expected to rise at a healthy rate. Natural progesterone-based solutions are the most effective in terms of generating prescriptions. The most significant income sources are drugs like Crinone and Prometrium. Increased financing initiatives, the expanding trend of home healthcare, and infrastructure development in the healthcare industry worldwide are other essential factors propelling the progesterone market forward. Positive patient outcomes related to natural progesterone have resulted in solid investment opportunities. Significant changes in hormonal interactions are responsible for better patient outcomes.

MARKET RESTRAINTS:

The lack of awareness about progesterone therapy's availability in underdeveloped countries and the therapy's adverse effects may limit the growth rate of the global progesterone market. Some of the adverse effects are severe breast discomfort, fever, joint aches, headache, dizziness, breast lumps, impaired vision, sudden vaginal bleeding, severe convulsions, constipation, nausea, and hair loss. Therefore, these adverse effects are the main challenges in utilizing progesterone on the market.

Impact of COVID-19 on the global progesterone market:

In December 2019, the World Health Organization designated the COVID-19 virus outbreak a public health emergency. The disease has spread to over 100 nations and resulted in increased deaths worldwide. COVID-19 patients who were unwell remained in the hospital and required ventilators. Progesterone is known to have anti-inflammatory effects, which might have helped prevent the frequently deadly 'cytokine storms' that can harm many people. A short treatment with a combination of estradiol and progesterone, given early and as a preventative measure in addition to SOC (standard of care), would avoid or minimize the cytokine storm while boosting antibody production and preventing catastrophic outcomes with no adverse effects. As a result, steroid immunomodulation will be achieved without immunosuppression. Furthermore, some reported research suggested that premenopausal women with greater progesterone levels than postmenopausal women had less severe COVID-19 illness.

REPORT COVERAGE:

This research report on the global progesterone market has been segmented & sub-segmented into the following categories.

Progesterone Market - By Type:

• Natural
• Synthetic

The natural progesterone segment held a significant share of the global progesterone market in 2022 and is predicted to grow at a promising CAGR during the forecast period. The growth of this segment is primarily driven by the products of natural progesterone, which has been studied to generate the maximum number of prescriptions and drugs like Prometrium and Crinone. Factors such as the growing demand for natural and bio-identical hormone therapies, rising preference for organic and plant-derived products and increasing awareness about the benefits of natural progesterone in managing hormonal imbalances boost the growth rate of the segment. The rising popularity of natural progesterone in fertility treatments and reproductive health, increasing number of applications of natural progesterone in menopause management and rising consumer demand for hormone replacement therapies with fewer side effects contribute to the segmental growth.

The synthetic segment is predicted to grow at a healthy CAGR during the forecast period. The wider availability and lower cost compared to natural progesterone majorly drive segmental growth. The established use of synthetic progesterone in pharmaceutical formulations, growing demand for synthetic progesterone in contraceptives and hormone replacement therapies and increasing number of R&D activities to enhance the efficacy and safety of synthetic progesterone boost the growth of the synthetic segment. The rising adoption of synthetic progesterone in the treatment of gynecological disorders and the growing use of synthetic progesterone in assisted reproductive technologies and in vitro fertilization further boost the segment’s growth rate.

Progesterone Market - By Mode of Delivery:

• Injectable
• Suspended form
• Oral

Based on the mode of delivery, the oral segment held the major share of the global market in 2022 and is expected to continue its dominion in the worldwide market during the forecast period due to the cognitive benefits of transdermal estradiol combined with oral progesterone for women with postmenopausal coupled with the studies that the combination of transdermal estradiol and oral progesterone can slow down cognitive decline. The convenience and non-invasive nature of oral progesterone administration, wide acceptance of oral progesterone formulations in hormone replacement therapies and growing use of oral progesterone in the treatment of menstrual irregularities primarily drive the growth of the oral segment. The preference for oral progesterone in maintaining pregnancy and preventing miscarriages and the rising availability of oral progesterone products in different dosage forms further promote segmental growth.

The injectable segment accounted for a considerable share of the global market in 2022 and is expected to grow at a healthy CAGR during the forecast period. The growing demand for injectable progesterone in assisted reproductive technologies, rising adoption of injectable progesterone in fertility treatments and in vitro fertilization and increasing usage of injectable progesterone in the management of high-risk pregnancies primarily propel the segmental growth. The growing preference for injectable progesterone in cases where oral or suspended forms may not be effective or suitable and the increasing number of applications of injectable progesterone in hormone replacement therapies and gynecological disorders further boost the growth rate of the segment.

Progesterone Market - By Application:

• Regulation of the Menstrual Cycle
• Dysfunctional Uterine Bleeding
• Endometrial Cancer
• Contraception
• Hyperplastic Precursor Lesions

Based on application, the regulation of the menstrual cycle segment held the major share of the global market in 2022 and is predicted to grow at a prominent CAGR during the forecast period. Factors such as the rising prevalence of menstrual irregularities and disorders, increasing demand for hormonal therapies to regulate menstrual cycles and growing awareness about the benefits of progesterone in managing menstrual disorders drive the growth of the regulation of the menstrual cycle segment.

Progesterone Market – By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America held the largest share of the global market in 2022 and the domination of the North American region in the global market is likely to continue throughout the forecast period. The presence of international market participants and rigorous R&D efforts by the market participants to ensure high medical standards boost the North American market growth. The rising prevalence of hormonal disorders and related conditions, increasing adoption of hormone replacement therapies, favorable reimbursement policies for hormone therapies and growing advancements in healthcare infrastructure and availability of advanced diagnostic techniques in North America further drive the North American progesterone market growth. The U.S. had the leading share of the North American market in 2022.

The European region is anticipated to grow at a notable CAGR during the forecast period. The growing incidence of abnormal uterine bleeding and amenorrhea among the EU female population is one of the major factors promoting the progesterone market in the European region. The growing awareness about hormonal imbalances and related disorders, increasing demand for hormone replacement therapies and fertility treatments, favorable government initiatives promoting women's health and growing number of investments in research and development of progesterone-based treatments in Europe further contribute to the European market growth. UK and Germany are anticipated to hold a considerable share of the European region during the forecast period. 

The Asia-Pacific progesterone market is predicted to grow quickly during the forecast period due to heightened awareness and a greater focus on eliminating hormonal deficits by healthcare professionals. The presence of a large population base, increasing healthcare expenditure, rising awareness about hormonal disorders, the availability of treatment options, rapid adoption of hormone replacement therapies in the aging population and growing emphasis on improving women's healthcare infrastructure contribute to the progesterone market growth in the Asia-Pacific region. China and India are predicted to account for the major share of the APAC market during the forecast period.

The Latin American regional market is predicted to account for a considerable share of the global market during the forecast period due to the rising prevalence of hormonal disorders and gynecological conditions, rising demand for fertility treatments and hormone replacement therapies, improving access to healthcare services in rural areas and growing investments in healthcare infrastructure and pharmaceutical industry.

The MEA market is estimated to grow at a moderate CAGR during the forecast period.

KEY MARKET PLAYERS:

Estrellas Life Sciences Private Limited, Bionpharma Inc., Sofgen Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., Virtus Pharmaceuticals Llc, Bluebell Pharma Group Company, Aquatic Remedies Pvt. Ltd., Intas Pharmaceuticals Ltd., Shanghai Yijing Industrial Co., Ltd., and Wuhan Honor Bio-Pharm Co., Ltd. are some of the major players in the global progesterone market.

RECENT MARKET DEVELOPMENTS:

• Mankind Pharma introduced generic Dydrogesterone tablets in India in December 2019 to treat infertility and pregnancy-related problems. 
• A survey on progesterone to prevent preterm delivery was released on November 17, 2017, by Wayne State University's Office of the Vice President for Research. This therapy uses vaginal progesterone to minimize the risk of preterm delivery, neonatal problems, and infant mortality in pregnant women with a short cervix.